Nonsteroidal anti-inflammatory drugs and aspirin: A comparison of the antiplatelet effects

American Journal of Therapeutics

Volumn 4, Issue 2-3, 1997, Pages 62-65

  Cheng, Jen Chieh ^a,b   Siegel, Lori B ^a   Katari, Bhanumathi ^a   Traynoff, Stephanie A ^a   Ro, Jae O ^a  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

adenosine diphosphate; aspirin; collagen; nonsteroidal anti inflammatory drugs; platelet aggregation; ristocetin; sodium arachidonate

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANALGESIC AGENT; ANTITHROMBOCYTIC AGENT; ARACHIDONIC ACID; COLLAGEN; DICLOFENAC; DIFLUNISAL; IBUPROFEN; INDOMETACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; RISTOCETIN; SALSALATE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION;

EID: 0031010646     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-199702000-00002     Document Type: Article

References (16)

1. Steering Committee of the Physician's Health Study Research Group: Final report on the aspirin component of the ongoing Physician's Health Study. N Engl J Med 1989;321:129-135.
2. The Anturane Reinfarction Trial Research Group: Sulfinpyrazone in the prevention of sudden death after myocardial infarction. N Engl J Med 1980;302:250-256.
3. The Anturane Reinfarction Italian Study Group: Sulfinpyrazone in postmyocardial infarction. Lancet 1982;1: 237-245.
4. Temple R, Pledger GW: The PDA's critique of the Anturane Reinfarction Trial. N Engl J Med 1980;300:1488-1492.
5. Mitchell JRA: Secondary prevention of myocardial infarction - the present state of the ART. Br Med J 1980;1: 1128-1130.
6. ISIS-2 Collaborative Group: Randomized trial of intravenous streptokinase, oral aspirin, both, or either among 17, 187 cases of suspected acute myocardial infarction. Lancet 1988;2:349-360.
7. Anti Platelet Trialists' Collaboration: Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1988;296:320-331.
8. Ali M, McDonald JD: Reversible and irreversible inhibition of platelet cyclooxygenase and serotonin release by nonsteroidal antiinflammatory drugs. Thromb Res 1978; 13:1957-1965.
9. Ryan WL, Hakenkamp K, Sullivan E: A new platelet function test. Thromb Res 1990;58:163-173.
10. Patrignani P, Filabozzi P, Patrono C: Selective cumulative inhibition of platelet thromboxane production by low dose aspirin in healthy subjects. J Clin Invest 1982; 69:1366-1372.
11. Jaffe EA, Weksler BB: Recovery of endothelial cell prostacyclin production after inhibition by low dose of aspirin. J Clin Invest 1979;63:532-535.
12. Miller K, Frishman WH: Platelets and antiplatelet therapy in ischemic heart disease. Med Clin North Am 1988;72:117-184.
13. Gent M, Easton JD, Hachinski VC, et al.: The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989;1:1215-1220.
14. Hass WK, Easton JD, Adams HP: A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989;321:501-507.
15. Schomig A, Neumann FJ, Kastrat A, et al.: A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary artery stents. N Engl J Med 1996;334:1084-1089.
16. Frishman WH, Burns B, Atac B, et al.: Novel antiplatelet therapies for treatment of patients with ischemic heart disease: Inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor. Am Heart J 1995;130:877-892.